Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are considered the standard treatment for patients with neovascular age-related macular degeneration (AMD), diabetic retinopathy (DR), and macular edema secondary to retinal vein occlusion. This evidence concerns the gene VEGFA and wet macular degeneration.